Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

Core Insights - Oculis Holding AG has completed enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops targeting diabetic macular edema (DME), with over 800 patients enrolled across 119 sites [1][2][7] - Topline data from these trials is expected in Q2 2026, followed by a New Drug Application (NDA) submission to the FDA [2][4][10] - If approved, OCS-01 will be the first topical eye drop treatment for DME, addressing significant unmet medical needs [3][6] Company Overview - Oculis is a global biopharmaceutical company focused on innovative treatments for ophthalmic and neuro-ophthalmic diseases [1][11] - The company is developing OCS-01 as a non-invasive alternative to current invasive treatments for DME, which typically require injections [6][11] - Oculis' proprietary OPTIREACH technology enhances drug delivery to the retina, improving treatment accessibility [6][11] Industry Context - DME is a leading cause of visual loss and legal blindness among diabetic patients, currently affecting approximately 37 million people globally, with projections of 53 million by 2040 [9] - There is a critical need for effective and less burdensome treatments for DME, as existing therapies often involve invasive procedures [9][10]